Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Holding CNCR?
Track your performance easily
CNCR Price & Analysis
CNCR ETF Chart & Stats
Day’s Range― - ―
52-Week Range$10.41 - $17.96
Previous Close$13.42
VolumeN/A
Average Volume (3M)3.60K
AUM11.09M
NAV13.48
Expense Ratio0.79%
Holdings Count78
Beta1.63
Inception DateOct 13, 2015
Last Dividend Ex-Date
Dec 29, 2021Dividend YieldN/A
Shares Outstanding830,814
Standard Deviation0.09
10 Day Avg. Volume2,931
30 Day Avg. Volume3,604
Alpha-0.01
Loncar Cancer Immunotherapy ETF (CNCR) Fund Flow Chart
Loncar Cancer Immunotherapy ETF (CNCR) 1 year Net Flows: -$3M
CNCR ETF News
PremiumCompany Announcements
Zymeworks to Showcase Innovations at Investor Conferences
PremiumCompany Announcements
Zymeworks Secures FDA Approval for ZiiheraCNCR ETF FAQ
What was CNCR’s price range in the past 12 months?
CNCR lowest ETF price was $10.41 and its highest was $17.96 in the past 12 months.
What is the AUM of CNCR?
As of Nov 19, 2024 The AUM of CNCR is 11.09M.
Is CNCR overvalued?
According to Wall Street analysts CNCR’s price is currently Undervalued.
Does CNCR pay dividends?
CNCR pays a Annually dividend of $1.85 which represents an annual dividend yield of N/A. See more information on CNCR dividends here
How many shares outstanding does CNCR have?
CNCR has 830,814 shares outstanding.
Which hedge fund is a major shareholder of CNCR?
Currently, no hedge funds are holding shares in CNCR
CNCR ETF Smart Score
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Immunitybio Inc
2.29%
Monte Rosa Therapeutics, Inc.
2.21%
Revolution Medicines, Inc.
1.90%
Exelixis
1.87%
Apollomics Inc.
1.85%
Zymeworks
1.77%
Enliven Therapeutics, Inc.
1.75%
Bristol-Myers Squibb Company
1.74%
Arcellx, Inc.
1.70%
Mersana Therapeutics
1.68%
Total18.76%
ETF Description
Loncar Cancer Immunotherapy ETF
CNCR tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products.